Marcel Imwinkelried, CEO, Siegfried, a CDMO of drug substances and drug products, reported on key acquisitions by the company to increase its small-molecule drug-substance capacity in the US and Australia at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.  

Siegfried announced in January (January 2026) that it was acquiring the drug-substance business of the Noramco Group, and Extractas Bioscience. The acquired businesses include three small-molecule drug substances sites with approximately 400 employees. The acquisitions included: (1) Noramco’s  commercial-scale manufacturing site in Wilmington, Delaware; (2) Purisys’ (a Noramco subsidiary) clinical active pharmaceutical ingredient (API) development and manufacturing facility in Athens, Georgia; and (3) Extractas Bioscience, a manufacturer of purified products based in Westbury, Tasmania, Australia.  

Siegfried plans to expand its synthesis business in the US by optimizing its controlled-substance capacity across the newly acquired Wilmington site and its nearby Pennsville, New Jersey, site.   

As a result of this sale, Halo Pharma, a CDMO of drug products purchased by Noramco in 2023, will become a stand-alone company. Halo Pharma was purchased by the Noramco Group from Cambrex in 2023. With the sale of the API-related assets of the Noramco Group, Halo will serve as a dedicated platform for drug-product CDMO services.